Professor of Medicine, University of California at Los Angeles, Los Angeles, CA, USA.
Expert Rev Clin Pharmacol. 2009 Jul;2(4):359-71. doi: 10.1586/ecp.09.17.
Knee osteoarthritis is the most common form of arthritis. Given the aging of the world's population, the burden of this disease is expected to increase significantly over the next few decades. As a pharmacological agent, glucosamine has been investigated for the treatment of symptoms and progression of knee osteoarthritis, demonstrating symptomatic and disease-modifying effects. However, among the glucosamine studies conducted to date in knee osteoarthritis, there have been conflicting results due to differences and/or weaknesses in study design and sample size, in addition to product formulation, salt and quality. This review describes the current knowledge regarding the pharmacokinetics of glucosamine to provide a means for the interpretation of the pharmacodynamic and clinical efficacy results obtained in the different clinical trials.
膝骨关节炎是最常见的关节炎形式。鉴于世界人口老龄化，预计在未来几十年内，这种疾病的负担将显著增加。作为一种药物制剂，氨基葡萄糖已被研究用于治疗膝骨关节炎的症状和进展，显示出症状和疾病改善的效果。然而，在迄今为止针对膝骨关节炎进行的氨基葡萄糖研究中，由于研究设计和样本量的差异和/或弱点，以及产品配方、盐和质量的不同，结果存在冲突。本文综述了氨基葡萄糖药代动力学的最新知识，为解释不同临床试验中获得的药效学和临床疗效结果提供了一种方法。
